Seasonal Allergic Rhinitis is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Seasonal Allergic Rhinitis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Seasonal Allergic Rhinitis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Seasonal Allergic Rhinitis overview
Seasonal allergic rhinitis (SAR), commonly referred to as hay fever, is an inflammatory condition affecting the upper airways in response to exposure to airborne allergens, typically pollen from trees, grasses, and weeds, particularly prevalent in certain seasons. This condition manifests in sensitized individuals, giving rise to symptoms such as sneezing, nasal congestion, a runny nose, itchy or watery eyes, and fatigue. SAR involves an immune system response, with the release of histamines and other chemicals triggered by exposure to allergens. While SAR itself doesn’t pose a serious health threat, its impact on the quality of life for those affected can be substantial. Management strategies often include allergen avoidance, the use of over-the-counter or prescription antihistamines, nasal corticosteroids, and, in severe cases, allergen immunotherapy.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Seasonal Allergic Rhinitis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
